Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib
We describe below the design of dal-GenE, a precision medicine, placebo-controlled clinical outcome trial of dalcetrapib in patients with a recent acute myocardial infarction with the unique feature of selecting only those with the AA genotype at rs1967309 in the ADCY9 gene.
Source: American Heart Journal - Category: Cardiology Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Genetics | Heart | Heart Attack | Stroke | Study